At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Leukoplakia, Oral. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukoplakia, Oral
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartDec 2018
Primary CompletionSep 2022
Study CompletionAug 2024
TodayJul 2026
First PostedOct 2, 2018
Enrollment StartDec 5, 2018
Primary CompletionSep 1, 2022
Study CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.8 years ago
Interventions
Nivolumabdrug
Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.